Log in

Relevant bibliographies by topics / Drug Resistance / Journal articles

To see the other types of publications on this topic, follow the link: Drug Resistance.

Journal articles on the topic 'Drug Resistance'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug Resistance.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

K, Tiwari. "Drug Resistance: Challenges and Updates." Journal of Natural & Ayurvedic Medicine 3, no. 3 (2019): 1–2. http://dx.doi.org/10.23880/jonam-16000196.

Full text

Abstract:

Use of antibiotics increased dramatically in last two decades. To cure most of the diseases broad spectrum antibiotics given. Human society and healthcare is going in wrong direction. One way the pharmaceutical companies are making huge money from it. The other way around is the overuse of these antibiotics, by patients knowing or unknowingly, not only making pathogens adapted but also the normal flora organisms becoming pathogens in coming future? Present article highlight the issues and possible solution of the present scenario.

APA, Harvard, Vancouver, ISO, and other styles

2

T.V., Sowjanya* B. Akhila N. Ahalya T. Sai Ram T. Maneesha V. Pavithra. "Drug Resistance In Various Disorders." International Journal in Pharmaceutical Sciences 2, no. 2 (2024): 558–64. https://doi.org/10.5281/zenodo.10684813.

Full text

Abstract:

Drug resistance is the ability of microorganisms, such as bacteria, viruses, or parasites, to withstand the effects of drugs that were intended to kill or inhibit their growth. In developed countries, drug resistance is the primary cause of death, the burden of infectious diseases is comparatively greater, and patients with a resistance are less likely to be able to afford secondary line treatments, which typically have more complex regimens than first line drugs. Nowadays, antibiotic resistance is increasing. Some of the common drug resistances like Bacteria, Cancer, Diabetes, Leprosy, and HI

APA, Harvard, Vancouver, ISO, and other styles

3

Singh, Amresh Kumar. "Resistance patterns and trends of extensively drug-resistant tuberculosis: 5-year experience." Journal of Microbiology and Infectious Diseases 03, no. 04 (2013): 169–75. http://dx.doi.org/10.5799/ahinjs.02.2013.04.0103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Dyary, Hiewa Othman. "Veterinary Anthelmintics and Anthelmintic Drug Resistance." Journal of Zankoy Sulaimani - Part A 18, no. 1 (2015): 191–206. http://dx.doi.org/10.17656/jzs.10463.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Çelik, Cem. "Increasing antimicrobial resistance in nosocomial pathogens; multidrug-resistant extensively drug-resistant and pandrug-resistant Acinetobacter baumannii." Journal of Microbiology and Infectious Diseases 4, no. 1 (2014): 7–12. http://dx.doi.org/10.5799/ahinjs.02.2014.01.0116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Xiaoping, Zhang, and Yu Xiangmin. "Research Progress on Drug-Resistant Bacteria." International Journal of Sciences Volume 8, no. 2019-06 (2019): 1–5. https://doi.org/10.5281/zenodo.3350755.

Full text

Abstract:

More and more microorganisms have developed drug resistance with the use of antibiotics, and some microorganisms have multi-drug resistance. Therefore, bacterial resistant antibiotic is a serious problem to treating infectious diseases in recent years all over the world. This paper briefly reviews the research progress of bacterial resistance mechanisms all over the world, and provides theoretical basis for exploring effective prevention measures and rational use antibiotics in clinical.Read Complete Article at ijSciences: V82019052079 AND DOI: http://dx.doi.org/10.18483/ijSci.2079

APA, Harvard, Vancouver, ISO, and other styles

7

Giaccone, Giuseppe, and Herbert M. Pinedo. "Drug Resistance." Oncologist 1, no. 1-2 (1996): 82–87. http://dx.doi.org/10.1634/theoncologist.1-1-82.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hochhauser, D., and A. L. Harris. "Drug resistance." British Medical Bulletin 47, no. 1 (1991): 178–96. http://dx.doi.org/10.1093/oxfordjournals.bmb.a072454.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Prichard, R. K. "Drug resistance." International Journal for Parasitology 29, no. 1 (1999): 137–38. http://dx.doi.org/10.1016/s0020-7519(98)00191-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Texidó, Gemma, and Jürgen Moll. "Drug resistance." Drug Discovery Today: Technologies 11 (March 2014): 1–3. http://dx.doi.org/10.1016/j.ddtec.2014.03.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Köser, Claudio U., Babak Javid, Kathleen Liddell, et al. "Drug-resistance mechanisms and tuberculosis drugs." Lancet 385, no. 9965 (2015): 305–7. http://dx.doi.org/10.1016/s0140-6736(14)62450-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Coen, Donald M., and Richard J. Whitley. "Antiviral drugs and antiviral drug resistance." Current Opinion in Virology 1, no. 6 (2011): 545–47. http://dx.doi.org/10.1016/j.coviro.2011.10.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hall, Andrew G., and Julie Irving. "New drugs, new drug resistance mechanisms." Expert Review of Anticancer Therapy 2, no. 3 (2002): 239–340. http://dx.doi.org/10.1586/14737140.2.3.239.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Kumar, Saurabh, and Richa Prasad Mahato. "DRUG RESISTANCE AND RESISTANCE REVERSAL STRATEGIES IN MALARIA PARASITE." Journal of microbiology, biotechnology and food sciences 13, no. 5 (2024): e10384. http://dx.doi.org/10.55251/jmbfs.10384.

Full text

Abstract:

The public health care system is currently facing a major problem with malaria. Globally, malarial deaths have decreased by an estimated 40% in the past two decades because of the clinically effective drugs (artemisinin-based combination therapies) against Plasmodium falciparum. In recent years, P falciparum develop resistance against all antimalarial drugs and then becomes developed multidrug resistance that a major challenge. Even though drug discovery programs have made substantial progress in the past decade, the potential for new drugs/combinations to improve the effectiveness of current

APA, Harvard, Vancouver, ISO, and other styles

15

Yusuf, Yenni. "ANTI-MALARIAL DRUG RESISTANCE." Majalah Kedokteran Andalas 37, no. 1 (2015): 64. http://dx.doi.org/10.22338/mka.v37.i1.p64-69.2014.

Full text

Abstract:

AbstrakTujuan studi ini adalah untuk menjelaskan mekanisme resistensi parasit malaria danusaha-usaha yang dapat dilakukan untuk menghadapi munculnya strain parasit yangresisten terhadap artemisinin. Metode yang digunakan adalah studi kepustakaan. ResistensiP.falciparum terhadap obat-obat anti malaria disebabkan oleh perubahan spontan yangterjadi pada beberapa gen seperti P.falciparum multi drug resistance1 (Pfmdr1), P.falciparumchloroquine transporter (Pfcrt), P.falciparum dihydropteroate synthase (Pfdhps), P.falciparumdihydrofolate reductase (Pfdhfr), and P.falciparum multidrug resistance-ass

APA, Harvard, Vancouver, ISO, and other styles

16

Kennedy, David A., and Andrew F. Read. "Why does drug resistance readily evolve but vaccine resistance does not?" Proceedings of the Royal Society B: Biological Sciences 284, no. 1851 (2017): 20162562. http://dx.doi.org/10.1098/rspb.2016.2562.

Full text

Abstract:

Why is drug resistance common and vaccine resistance rare? Drugs and vaccines both impose substantial pressure on pathogen populations to evolve resistance and indeed, drug resistance typically emerges soon after the introduction of a drug. But vaccine resistance has only rarely emerged. Using well-established principles of population genetics and evolutionary ecology, we argue that two key differences between vaccines and drugs explain why vaccines have so far proved more robust against evolution than drugs. First, vaccines tend to work prophylactically while drugs tend to work therapeuticall

APA, Harvard, Vancouver, ISO, and other styles

17

Nyce, J., S. Leonard, D. Canupp, S. Schulz, and S. Wong. "Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance." Proceedings of the National Academy of Sciences 90, no. 7 (1993): 2960–64. http://dx.doi.org/10.1073/pnas.90.7.2960.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Hossain, Chowdhury Mobaswar, Lisa Kathleen Ryan, Meeta Gera, et al. "Antifungals and Drug Resistance." Encyclopedia 2, no. 4 (2022): 1722–37. http://dx.doi.org/10.3390/encyclopedia2040118.

Full text

Abstract:

Antifungal drugs prevent topical or invasive fungal infections (mycoses) either by stopping growth of fungi (termed fungistatic) or by killing the fungal cells (termed fungicidal). Antibiotics also prevent bacterial infections through either bacteriostatic or bactericidal mechanisms. These microorganisms successfully develop resistance against conventional drugs that are designed to kill or stop them from multiplying. When a fungus no longer responds to antifungal drug treatments and continues to grow, this is known as antifungal drug resistance. Bacteria have an amazing capacity to become res

APA, Harvard, Vancouver, ISO, and other styles

19

Perfect, John R., and Gary M. Cox. "Drug resistance in Cryptococcus neoformans." Drug Resistance Updates 2, no. 4 (1999): 259–69. http://dx.doi.org/10.1054/drup.1999.0090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Croft, Simon L., Shyam Sundar, and Alan H. Fairlamb. "Drug Resistance in Leishmaniasis." Clinical Microbiology Reviews 19, no. 1 (2006): 111–26. http://dx.doi.org/10.1128/cmr.19.1.111-126.2006.

Full text

Abstract:

SUMMARY Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant differences in the sensitivity of these species both to the standard drugs, for example, pentavalent antimonials and miltefosine, and those on clinical trial, for example, paromomycin. Over 60% of patients with visceral leishmaniasis in Bihar State, India, do not respond to treatment with pentavalent antimonials. This is now considered to be due to acquired resistance. Although this class of drugs ha

APA, Harvard, Vancouver, ISO, and other styles

21

de Koning, Harry P. "Drug resistance in protozoan parasites." Emerging Topics in Life Sciences 1, no. 6 (2017): 627–32. http://dx.doi.org/10.1042/etls20170113.

Full text

Abstract:

As with all other anti-infectives (antibiotics, anti-viral drugs, and anthelminthics), the limited arsenal of anti-protozoal drugs is being depleted by a combination of two factors: increasing drug resistance and the failure to replace old and often shamefully inadequate drugs, including those compromised by (cross)-resistance, through the development of new anti-parasitics. Both factors are equally to blame: a leaking bathtub may have plenty of water if the tap is left open; if not, it will soon be empty. Here, I will reflect on the factors that contribute to the drug resistance emergency tha

APA, Harvard, Vancouver, ISO, and other styles

22

Rabab, Batool, Imran Muhammad, Hafeez Kandhro Abdul, Salahuddin Naseem, and K. H. Uddin Muhammad. "Resistance Patterns among Multidrug-Resistant Tuberculosis Patients: A Multi-Center Study from Pakistan." International Journal of Endorsing Health Science Research 5, no. 4 (2017): 07–11. https://doi.org/10.29052/IJEHSR.v5.i4.2017.07-11.

Full text

Abstract:

Abstract <strong>Background:</strong> The high burden of multi-drug resistance tuberculosis (MDR TB) is a matter of great concern.  The increasing resistance to anti tuberculosis drugs has been the area of growing concern and are posing threats to TB control. The aim of this study was to evaluate the drug resistance patterns for the first line and second line anti-Tuberculosis drugs in multiple drug resistant tuberculosis (MDR-TB) patients. <strong>Method:</strong> The study was retrospective, observational, employing purposive, non-random sampling technique for data collection

APA, Harvard, Vancouver, ISO, and other styles

23

Wtorek, Karol, Angelika Długosz, and Anna Janecka. "Drug resistance in topoisomerase-targeting therapy." Postępy Higieny i Medycyny Doświadczalnej 72 (December 21, 2018): 1073–83. http://dx.doi.org/10.5604/01.3001.0012.8131.

Full text

Abstract:

Drug resistance is a well-known phenomenon that occurs when initially responsive to chemotherapy cancer cells become tolerant and elude further effectiveness of anticancer drugs. Based on their mechanism of action, anticancer drugs can be divided into cytotoxic-based agents and target-based agents. An important role among the therapeutics of the second group is played by drugs targeting topoisomerases, nuclear enzymes critical to DNA function and cell survival. These enzymes are cellular targets of several groups of anticancer agents which generate DNA damage in rapidly proliferating cancer ce

APA, Harvard, Vancouver, ISO, and other styles

24

Freire, Tomas Ferreira Amaro, Zhijian Hu, Kevin B. Wood, and Erida Gjini. "Modeling spatial evolution of multi-drug resistance under drug environmental gradients." PLOS Computational Biology 20, no. 5 (2024): e1012098. http://dx.doi.org/10.1371/journal.pcbi.1012098.

Full text

Abstract:

Multi-drug combinations to treat bacterial populations are at the forefront of approaches for infection control and prevention of antibiotic resistance. Although the evolution of antibiotic resistance has been theoretically studied with mathematical population dynamics models, extensions to spatial dynamics remain rare in the literature, including in particular spatial evolution of multi-drug resistance. In this study, we propose a reaction-diffusion system that describes the multi-drug evolution of bacteria based on a drug-concentration rescaling approach. We show how the resistance to drugs

APA, Harvard, Vancouver, ISO, and other styles

25

Kurt Yilmaz, Nese, and Celia A. Schiffer. "Introduction: Drug Resistance." Chemical Reviews 121, no. 6 (2021): 3235–37. http://dx.doi.org/10.1021/acs.chemrev.1c00118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Emery, VC. "Cytomegalovirus Drug Resistance." Antiviral Therapy 3, no. 4 (1998): 239–42. http://dx.doi.org/10.1177/135965359800300403.

Full text

Abstract:

Clinical resistance of cytomegalovirus (CMV) against the currently licensed antiviral drugs is becoming an increasingly recognized problem. This review focuses on the molecular basis of resistance and describes mutations in the UL54 DNA polymerase leading to resistance against cidofovir, foscarnet and ganciclovir. The review highlights two important developments in our appreciation of resistance. Firstly, the use of more rapid molecular based assays to detect genotypic resistance and secondly, the relationship between resistance profiles in multiple organ systems of the same host. Finally, the

APA, Harvard, Vancouver, ISO, and other styles

27

Clavel, François, and Allan J. Hance. "HIV Drug Resistance." New England Journal of Medicine 350, no. 10 (2004): 1023–35. http://dx.doi.org/10.1056/nejmra025195.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Richman, D. D. "HIV Drug Resistance." Annual Review of Pharmacology and Toxicology 33, no. 1 (1993): 149–64. http://dx.doi.org/10.1146/annurev.pa.33.040193.001053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Davies, Peter, and Damian Cullen. "Antituberculosis drug resistance." Clinical Medicine 9, no. 1 (2009): 91.1–91. http://dx.doi.org/10.7861/clinmedicine.9-1-91.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Perrin, Luc. "Drug resistance mutations." AIDS 18, no. 8 (2004): 1201–2. http://dx.doi.org/10.1097/00002030-200405210-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

White, Nicholas J. "Antimalarial drug resistance." Journal of Clinical Investigation 113, no. 8 (2004): 1084–92. http://dx.doi.org/10.1172/jci21682.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Tesio, Melania. "Starving Drug Resistance." HemaSphere 4, no. 6 (2020): e495. http://dx.doi.org/10.1097/hs9.0000000000000495.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Pizzorno, Andrés, Yacine Abed, and Guy Boivin. "Influenza Drug Resistance." Seminars in Respiratory and Critical Care Medicine 32, no. 04 (2011): 409–22. http://dx.doi.org/10.1055/s-0031-1283281.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

COEN, DONALD M. "Antiviral Drug Resistance." Annals of the New York Academy of Sciences 616, no. 1 AIDS (1990): 224–36. http://dx.doi.org/10.1111/j.1749-6632.1990.tb17843.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Weitzman, Jonathan B. "Cancer drug resistance." Genome Biology 2 (2001): spotlight—20010626–01. http://dx.doi.org/10.1186/gb-spotlight-20010626-01.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Smirnov, G. B. "Bacterial drug-resistance." Molecular Genetics, Microbiology and Virology (Russian) 42, no. 3 (2024): 43. http://dx.doi.org/10.17116/molgen20244203143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Flintoff, Wayne F. "Acquired drug resistance." Genome 31, no. 1 (1989): 447. http://dx.doi.org/10.1139/g89-073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gold, Howard S., and Robert C. Moellering. "Antimicrobial-Drug Resistance." New England Journal of Medicine 335, no. 19 (1996): 1445–53. http://dx.doi.org/10.1056/nejm199611073351907.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Phelps, Charles E. "Bug/Drug Resistance." Medical Care 27, no. 2 (1989): 194–203. http://dx.doi.org/10.1097/00005650-198902000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Robertson, John D. "CANCER DRUG RESISTANCE." Shock 26, no. 6 (2006): 638. http://dx.doi.org/10.1097/01.shk.0000248599.09507.90.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

RICHMAN, DOUGLAS D. "HIV Drug Resistance." AIDS Research and Human Retroviruses 8, no. 6 (1992): 1065–71. http://dx.doi.org/10.1089/aid.1992.8.1065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Schmit, Jean-Claude. "HIV drug resistance." HIV Clinical Trials 3, no. 3 (2002): 225–26. http://dx.doi.org/10.1310/kmkn-ke48-2gwu-g0he.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Richman, Douglas D. "Viral drug resistance." Current Opinion in Infectious Diseases 3, no. 6 (1990): 819–23. http://dx.doi.org/10.1097/00001432-199012000-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Loeffler, Juergen, and David A. Stevens. "Antifungal Drug Resistance." Clinical Infectious Diseases 36, Supplement_1 (2003): S31—S41. http://dx.doi.org/10.1086/344658.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Richman, Douglas D. "Antiviral drug resistance." Antiviral Research 71, no. 2-3 (2006): 117–21. http://dx.doi.org/10.1016/j.antiviral.2006.03.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Calmy, Alexandra, Fernando Pascual, and Nathan Ford. "HIV Drug Resistance." New England Journal of Medicine 350, no. 26 (2004): 2720–21. http://dx.doi.org/10.1056/nejm200406243502621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Pillay, D., and A. M. Geddes. "Antiviral drug resistance." BMJ 313, no. 7056 (1996): 503–4. http://dx.doi.org/10.1136/bmj.313.7056.503.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Richman, Douglas D. "Antiretroviral drug resistance." AIDS 5, Supplement (1991): 189. http://dx.doi.org/10.1097/00002030-199101001-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Richman, Douglas D. "HIV DRUG RESISTANCE." AIDS 8, Supplement 4 (1994): S3. http://dx.doi.org/10.1097/00002030-199411004-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

STEVENSON, AUDREY M. "Emerging Drug Resistance." MCN, The American Journal of Maternal/Child Nursing 23, no. 4 (1998): 216. http://dx.doi.org/10.1097/00005721-199807000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!